MPM Oncology Impact Management »

Corvus Pharmaceuticals shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Corvus Pharmaceuticals (CRVS) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Corvus Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Corvus Pharmaceuticals held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Corvus Pharmaceuticals by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $21M 2.7M 7.70

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Madrigal Pharmaceuticals Common (MDGL)
Liquidia Corp Common (LQDA)
Trevi Therapeutics Common (TRVI)
Edgewise Therapeutics Common (EWTX)
Revolution Medicines Common (RVMD)
Agios Pharmaceuticals Common (AGIO)
Uniqure NV Common (QURE)
PTC Therapeutics Common (PTCT)
Syndax Pharmaceuticals Common (SNDX)
Dyne Therapeutics Common (DYN)
Tarsus Pharmaceuticals Common (TARS)
Stoke Therapeutics Common (STOK)
Alumis Common (ALMS)
Urogen Pharma Common (URGN)

View all positions for MPM Oncology Impact Management

Top funds holding Corvus Pharmaceuticals

OrbiMed Advisors
BlackRock
Vanguard Group
Adams Street Partners
Point72 Asset Management
State Street Corporation
MPM Oncology Impact Management
Vivo Capital
Foresite Capital Management VI
Geode Capital Management
Perceptive Advisors
DCF Advisers
Susquehanna International
Goldman Sachs Group
Logos Global Management

View all funds holding Corvus Pharmaceuticals